{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:57:31Z","timestamp":1772837851088,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012478","name":"Secretaria de Ciencia y Tecnolog\u00eda - Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["PID CONSOLIDAR. Res. N\u00b0 411\/18."],"award-info":[{"award-number":["PID CONSOLIDAR. Res. N\u00b0 411\/18."]}],"id":[{"id":"10.13039\/100012478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03101-y","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T14:44:26Z","timestamp":1744901066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Amorphous State of the Antiepileptic Clobazam: Preparation and Characterization"],"prefix":"10.1208","volume":"26","author":[{"given":"Marina M.","family":"Marcos Valdez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E.","family":"Bertotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio E.","family":"Fandi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando P.","family":"Cometto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-6328","authenticated-orcid":false,"given":"Norma R.","family":"Sperandeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"7","key":"3101_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2174\/092986709787549299","volume":"16","author":"J Lu","year":"2009","unstructured":"Lu J, Rohani S. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Curr Med Chem. 2009;16(7):884\u2013905. https:\/\/doi.org\/10.2174\/092986709787549299.","journal-title":"Curr Med Chem"},{"issue":"32","key":"3101_CR2","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.2174\/1381612822666160804100036","volume":"22","author":"A Talaczynska","year":"2016","unstructured":"Talaczynska A, Dzitko J, Cielecka-Piontek J. Benefits and limitations of polymorphic and amorphous forms of active pharmaceutical ingredients. Curr Pharm Des. 2016;22(32):4975\u201380. https:\/\/doi.org\/10.2174\/1381612822666160804100036.","journal-title":"Curr Pharm Des"},{"key":"3101_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.addr.2017.03.002","volume":"17","author":"AM Healy","year":"2017","unstructured":"Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. Adv Drug Deliv Rev. 2017;17:5\u201346. https:\/\/doi.org\/10.1016\/j.addr.2017.03.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"3101_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/0022-3093(95)00502-1","volume":"195","author":"PK Gupta","year":"1996","unstructured":"Gupta PK. Non-crystalline solids: glasses and amorphous solids. J Non-Cryst Solids. 1996;195(1\u20132):158\u201364. https:\/\/doi.org\/10.1016\/0022-3093(95)00502-1.","journal-title":"J Non-Cryst Solids"},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.addr.2015.12.013","volume":"100","author":"S Thakral","year":"2016","unstructured":"Thakral S, Terban MW, Thakral NK, Suryanarayanan R. Recent advances in the characterization of amorphous pharmaceuticals by X-ray diffractometry. Adv Drug Deliv Rev. 2016;100:183\u201393. https:\/\/doi.org\/10.1016\/j.addr.2015.12.013.","journal-title":"Adv Drug Deliv Rev"},{"key":"3101_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0169-409X(01)00098-9","volume":"48","author":"L Yu","year":"2001","unstructured":"Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27\u201342. https:\/\/doi.org\/10.1016\/S0169-409X(01)00098-9.","journal-title":"Adv Drug Deliv Rev"},{"key":"3101_CR7","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/mp500303a","volume":"11","author":"A Alhalaweh","year":"2014","unstructured":"Alhalaweh A, Alzghoul A, Kaialy W, Mahlin D, Bergstr\u00f6m CAS. Computational predictions of glass-forming ability and crystallization tendency of drug molecules. Mol Pharmaceutics. 2014;11:3123\u201332. https:\/\/doi.org\/10.1021\/mp500303a.","journal-title":"Mol Pharmaceutics"},{"key":"3101_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejpb.2016.11.031","volume":"112","author":"N Wyttenbach","year":"2017","unstructured":"Wyttenbach N, Kuentz M. Glass-forming ability of compounds in marketed amorphous drug products. Eur J Pharm Biopharm. 2017;112:204\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2016.11.031.","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"3101_CR9","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s11095-010-0269-5","volume":"27","author":"SB Murdande","year":"2010","unstructured":"Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res. 2010;27(12):2704\u201314. https:\/\/doi.org\/10.1007\/s11095-010-0269-5.","journal-title":"Pharm Res."},{"issue":"1","key":"3101_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.xphs.2024.08.029","volume":"114","author":"K Ueda","year":"2025","unstructured":"Ueda K, Moseson DE, Taylor LS. Amorphous solubility advantage: Theoretical considerations, experimental methods, and contemporary relevance. J Pharm Sci. 2025;114(1):18\u201339. https:\/\/doi.org\/10.1016\/j.xphs.2024.08.029.","journal-title":"J Pharm Sci"},{"issue":"4","key":"3101_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11095-009-0021-1","volume":"27","author":"DE Alonzo","year":"2010","unstructured":"Alonzo DE, Zhang GG, Zhou D, Gao Y, Taylor LS. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27(4):608\u201318. https:\/\/doi.org\/10.1007\/s11095-009-0021-1.","journal-title":"Pharm Res"},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1021\/acs.molpharmaceut.1c00081","volume":"18","author":"S Valenti","year":"2021","unstructured":"Valenti S, Barrio M, Negrier P, Romanini M, Macovez R, Tamarit J-L. Comparative physical study of three pharmaceutically active benzodiazepine derivatives: crystalline versus amorphous state and crystallization tendency. Mol Pharmaceutics. 2021;18:1819\u201332. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00081.","journal-title":"Mol Pharmaceutics"},{"issue":"2","key":"3101_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ejpb.2011.10.006","volume":"80","author":"P Karmwar","year":"2012","unstructured":"Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin. Eur J Pharm Biopharm. 2012;80(2):459\u201364. https:\/\/doi.org\/10.1016\/j.ejpb.2011.10.006.","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"3101_CR14","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/jps.2600831211","volume":"83","author":"M Yoshioka","year":"1994","unstructured":"Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83(12):1700\u20135. https:\/\/doi.org\/10.1002\/jps.2600831211.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3101_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jps.22774","volume":"01","author":"SD Clas","year":"2012","unstructured":"Clas SD, Lalonde K, Khougaz K, Dalton CR, Bilbeisi R. Detection of a minor amorphous phase in crystalline etoricoxib by dynamic mechanical analysis: comparison with Raman spectroscopy and modulated differential scanning calorimetry. J Pharm Sci. 2012;01(2):558\u201365. https:\/\/doi.org\/10.1002\/jps.22774.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3101_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijpharm.2005.09.029","volume":"307","author":"M Lappalainen","year":"2006","unstructured":"Lappalainen M, Pitk\u00e4nen I, Harjunen P. Quantification of low levels of amorphous content in sucrose by hyperDSC. Int J Pharm. 2006;307(2):150\u20135. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.09.029.","journal-title":"Int J Pharm"},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejpb.2023.01.008","volume":"184","author":"AB Moroni","year":"2023","unstructured":"Moroni AB, Perez Mayoral E, Lionello DF, Vega DR, Kaufman TS, Calvo NL. Solid-state properties of Nifurtimox. Preparation, analytical characterization, and stability of an amorphous phase. Eur J Pharm Biopharm. 2023;184:25\u201335. https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.008.","journal-title":"Eur J Pharm Biopharm."},{"issue":"2","key":"3101_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0883073812463609","volume":"28","author":"JW Wheless","year":"2013","unstructured":"Wheless JW, Phelps SJ. Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol. 2013;28(2):219\u201329. https:\/\/doi.org\/10.1177\/0883073812463609.","journal-title":"J Child Neurol"},{"issue":"1","key":"3101_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"YT Ng","year":"2007","unstructured":"Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1):138\u201344. https:\/\/doi.org\/10.1016\/j.nurt.2006.11.002.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3101_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.1313","volume":"59","author":"D Tolbert","year":"2019","unstructured":"Tolbert D, Larsen F. A Comprehensive overview of the clinical pharmacokinetics of clobazam. J Clin Pharmacol. 2019;59(1):7\u201319. https:\/\/doi.org\/10.1002\/jcph.1313.","journal-title":"J Clin Pharmacol."},{"key":"3101_CR21","unstructured":"DrugBank: clobazam. https:\/\/go.drugbank.com\/drugs\/DB00349. Accessed\u00a019 Mar 2025."},{"key":"3101_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/epi.16597","volume":"61","author":"R Odi","year":"2020","unstructured":"Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs\u2014From phenobarbital to cenobamate and beyond. Epilepsia. 2020;61:1543\u201352. https:\/\/doi.org\/10.1111\/epi.16597.","journal-title":"Epilepsia"},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1107\/S0108270185006667","volume":"C41","author":"HJ Butcher","year":"1985","unstructured":"Butcher HJ, Hamor TA. Structure of 7-Chloro- 1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H, SH)-dione (Clobazam), C16H13CIN202. Acta Cryst. 1985;C41:1081\u20133. https:\/\/doi.org\/10.1107\/S0108270185006667.","journal-title":"Acta Cryst"},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tca.2012.05.011","volume":"543","author":"S Toscani","year":"2012","unstructured":"Toscani S, Cornevin L, Burgot G. Weak interactions in clobazam\u2013lactose mixtures examined by differential scanning calorimetry: Comparison with the captopril\u2013lactose system. Thermochim Acta. 2012;543:197\u2013204. https:\/\/doi.org\/10.1016\/j.tca.2012.05.011.","journal-title":"Thermochim Acta"},{"issue":"9","key":"3101_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/jps.20424","volume":"94","author":"JE Patterson","year":"2005","unstructured":"Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J Pharm Sci. 2005;94(9):1998\u20132012. https:\/\/doi.org\/10.1002\/jps.20424.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3101_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3797\/scipharm.1209-10","volume":"81","author":"NR Sperandeo","year":"2013","unstructured":"Sperandeo NR, Faudone SN. Evidence of polymorphism on the antitrypanosomal naphthoquinone (4E)-2-(1H-Pyrazol-3-ylamino)-4-(1H-pyrazol-3-ylimino)naphthalen-1(4H)-one. Sci Pharm. 2013;81(3):855\u201364. https:\/\/doi.org\/10.3797\/scipharm.1209-10.","journal-title":"Sci Pharm"},{"key":"3101_CR27","unstructured":"Council of Europe. European Pharmacopoeia. 6.0. Strasbourg: Council of Europe, 2007. Clobazam; p. 1572\u20133."},{"issue":"4","key":"3101_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/jat\/2.4.147","volume":"2","author":"H Schuetz","year":"1978","unstructured":"Schuetz H. TLC data of hydrolysis products of 1,4-and 1,5-benzodiazepines and major metabolites. J Anal Toxicol. 1978;2(4):147\u20138. https:\/\/doi.org\/10.1093\/jat\/2.4.147.","journal-title":"J Anal Toxicol"},{"key":"3101_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0021-9673(01)90326-7","volume":"358","author":"M Chiarotti","year":"1986","unstructured":"Chiarotti M, De Giovanni N, Fiori A. Analysis of benzodiazepines: I chromatographic identification. J Chromatogr A. 1986;358:169\u201378. https:\/\/doi.org\/10.1016\/S0021-9673(01)90326-7.","journal-title":"J Chromatogr A"},{"key":"3101_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0368-2048(76)80015-1","volume":"8","author":"JH Scofield","year":"1976","unstructured":"Scofield JH. Hartree-slater subshell photoionization cross stions at 1254 and 1487 eV. J Electron Spectrosc Relat Phenom. 1976;8:129\u201337. https:\/\/doi.org\/10.1016\/0368-2048(76)80015-1.","journal-title":"J Electron Spectrosc Relat Phenom"},{"issue":"12","key":"3101_CR31","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1016\/j.xphs.2023.09.005","volume":"112","author":"MM Marcos Valdez","year":"2023","unstructured":"Marcos Valdez MM, Fandi\u00f1o OE, Faudone SN, Ayala AP, Caira MR, Sperandeo NR. Solid forms of the new antitrypanosomal 1-(4-acetamide-benzenesulfonyl)-benzimidazole: preparation and physicochemical characterization. J Pharm Sci. 2023;112(12):3233\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.005.","journal-title":"J Pharm Sci"},{"key":"3101_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejps.2010.03.003","volume":"40","author":"V Puri","year":"2010","unstructured":"Puri V, Dantuluri AK, Kumar M, Karar N, Bansal AK. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci. 2010;40:84\u201393. https:\/\/doi.org\/10.1016\/j.ejps.2010.03.003.","journal-title":"Eur J Pharm Sci"},{"issue":"03","key":"3101_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7324\/JAPS.2020.103008","volume":"10","author":"DE Kassuha","year":"2020","unstructured":"Kassuha DE, Bruno FP, Monti GA, Sperandeo NR. Pharmaceutical polymorphism of a 5\u00b4-O-oxalatoyl prodrug of zidovudine (azidothymidine). J Applied Pharm Sci. 2020;10(03):67\u201374. https:\/\/doi.org\/10.7324\/JAPS.2020.103008.","journal-title":"J Applied Pharm Sci."},{"issue":"2","key":"3101_CR34","doi-asserted-by":"publisher","first-page":"E223","DOI":"10.1208\/pt060232","volume":"6","author":"P Gupta","year":"2005","unstructured":"Gupta P, Bansal AK. Devitrification of amorphous celecoxib. AAPS PharmSciTech. 2005;6(2):E223\u201330. https:\/\/doi.org\/10.1208\/pt060232.","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"3101_CR35","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1021\/acs.jpcb.7b10105","volume":"122","author":"EO Kissi","year":"2018","unstructured":"Kissi EO, Grohganz H, L\u00f6bmann K, Ruggiero MT, Zeitler JA, Rades T. Glass-transition temperature of the \u03b2-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs. J Phys Chem B. 2018;122(10):2803\u20138. https:\/\/doi.org\/10.1021\/acs.jpcb.7b10105.","journal-title":"J Phys Chem B"},{"issue":"3\u20134","key":"3101_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejps.2009.04.005","volume":"37","author":"KA Graeser","year":"2009","unstructured":"Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur J Pharm Sci. 2009;37(3\u20134):492\u20138. https:\/\/doi.org\/10.1016\/j.ejps.2009.04.005.","journal-title":"Eur J Pharm Sci"},{"key":"3101_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/10837450.2013.871033","volume":"20","author":"DE Kassuha","year":"2015","unstructured":"Kassuha DE, Aiassa V, Bruno FP, Cuadra G, Sperandeo NR. Preparation and characterization of polymorphs of the glucocorticoid deflazacort. Pharm Dev Technol. 2015;20:401\u20139. https:\/\/doi.org\/10.3109\/10837450.2013.871033.","journal-title":"Pharm Dev Technol"},{"key":"3101_CR38","unstructured":"Muthu S, Prasath M, Arun Balaji R. Experimental and theoretical investigations of spectroscopic properties of clobazam. Rec Res Sci Tech. 2011;3(4):127\u201335. https:\/\/updatepublishing.com\/journal\/index.php\/rrst\/article\/view\/675. Accessed 19 Mar 2025."},{"key":"3101_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jpba.2017.01.051","volume":"137","author":"N Kumar","year":"2017","unstructured":"Kumar N, Devineni SR, Dubey SK, Kumar P. Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI\/MS and NMR. J Pharm Biomed Anal. 2017;137:268\u201378. https:\/\/doi.org\/10.1016\/j.jpba.2017.01.051.","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"3101_CR40","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/jps.22197","volume":"99","author":"JA Baird","year":"2010","unstructured":"Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99(9):3787\u2013806. https:\/\/doi.org\/10.1002\/jps.22197.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3101_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1208\/s12249-012-9801-8","volume":"13","author":"NS Trasi","year":"2012","unstructured":"Trasi NS, Byrn SR. Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds. AAPS PharmSciTech. 2012;13(3):772\u201384. https:\/\/doi.org\/10.1208\/s12249-012-9801-8.","journal-title":"AAPS PharmSciTech"},{"key":"3101_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1021\/cg700913m","volume":"8","author":"KA Graeser","year":"2008","unstructured":"Graeser KA, Strachan CJ, Patterson JE, Gordon KC, Rades T. Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Cryst Growth Des. 2008;8:128\u201335. https:\/\/doi.org\/10.1021\/cg700913m.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"3101_CR43","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/jps.23041","volume":"101","author":"JF Willart","year":"2012","unstructured":"Willart JF, Carpentier L, Dan\u00e8de F, Descamps M. Solid-state vitrification of crystalline griseofulvin by mechanical milling. J Pharm Sci. 2012;101(4):1570\u20137. https:\/\/doi.org\/10.1002\/jps.23041.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3101_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0378-5173(98)00338-X","volume":"179","author":"DQ Craig","year":"1999","unstructured":"Craig DQ, Royall PG, Kett VL, Hopton ML. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999;179(2):179\u2013207. https:\/\/doi.org\/10.1016\/S0378-5173(98)00338-X.","journal-title":"Int J Pharm"},{"issue":"13","key":"3101_CR45","doi-asserted-by":"publisher","first-page":"7848","DOI":"10.1021\/acs.chemrev.8b00510","volume":"119","author":"Q Zheng","year":"2019","unstructured":"Zheng Q, Zhang Y, Montazerian M, Gulbiten O, Mauro JC, Zanotto ED, et al. Understanding glass through differential scanning calorimetry. Chem Rev. 2019;119(13):7848\u2013939. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00510.","journal-title":"Chem Rev"},{"issue":"3","key":"3101_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ejpb.2008.02.001","volume":"69","author":"AM Kaushal","year":"2008","unstructured":"Kaushal AM, Bansal AK. Thermodynamic behavior of glassy state of structurally related compounds. Eur J Pharm Biopharm. 2008;69(3):1067\u201376. https:\/\/doi.org\/10.1016\/j.ejpb.2008.02.001.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3101_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/chir.22542","volume":"28","author":"R Sabia","year":"2016","unstructured":"Sabia R, De Martino M, Cavazzini A, Villani C. Dynamic behavior of clobazam on high-performance liquid chromatography chiral stationary phases. Chirality. 2016;28(1):17\u201321. https:\/\/doi.org\/10.1002\/chir.22542.","journal-title":"Chirality"},{"issue":"7","key":"3101_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1023\/A:1011902816175","volume":"15","author":"PG Royall","year":"1998","unstructured":"Royall PG, Craig DQ, Doherty C. Characterisation of the glass transition of an amorphous drug using modulated DSC. Pharm Res. 1998;15(7):1117\u201321. https:\/\/doi.org\/10.1023\/A:1011902816175.","journal-title":"Pharm Res"},{"issue":"8","key":"3101_CR49","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.polymertesting.2010.09.005","volume":"29","author":"CA Gracia-Fern\u00e1ndez","year":"2010","unstructured":"Gracia-Fern\u00e1ndez CA, G\u00f3mez-Barreiro S, L\u00f3pez-Beceiro J, Tarr\u00edo Saavedra J, Naya S, Artiaga R. Comparative study of the dynamic glass transition temperature by DMA and TMDSC. Polym Testing. 2010;29(8):1002\u20136. https:\/\/doi.org\/10.1016\/j.polymertesting.2010.09.005.","journal-title":"Polym Testing"},{"key":"3101_CR50","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1039\/C3SM51950C","volume":"9","author":"P Chatterjee","year":"2013","unstructured":"Chatterjee P, Hazra S. The hydrophilic\/hydrophobic nature of a Cl-terminated Si surface. Soft Matter. 2013;9:9799\u2013806. https:\/\/doi.org\/10.1039\/C3SM51950C.","journal-title":"Soft Matter"},{"key":"3101_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsadv.2022.100332","volume":"12","author":"DN Gopala Krishna","year":"2022","unstructured":"Gopala Krishna DN, Philip J. Review on surface-characterization applications of X-ray photoelectron spectroscopy (XPS): Recent developments and challenges. App Surf Sci Adv. 2022;12: 100332. https:\/\/doi.org\/10.1016\/j.apsadv.2022.100332.","journal-title":"App Surf Sci Adv"},{"issue":"2","key":"3101_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0378-5173(00)00341-0","volume":"198","author":"CA Prestidge","year":"2000","unstructured":"Prestidge CA, Tsatouhas G. Wettability studies of morphine sulfate powders. Int J Pharm. 2000;198(2):201\u201312. https:\/\/doi.org\/10.1016\/s0378-5173(00)00341-0.","journal-title":"Int J Pharm"},{"key":"3101_CR53","doi-asserted-by":"publisher","unstructured":"Mansour RSH, Deb PK, Tekade KR. Role of amorphous state in drug delivery. In Tekade KR, editor. Advances in Pharmaceutical Product Development and Research. Dosage Form Design Parameters, Vol II. Academic Press. 2018, Chapter 4, p.105\u201346. https:\/\/doi.org\/10.1016\/B978-0-12-814421-3.00004-X.","DOI":"10.1016\/B978-0-12-814421-3.00004-X"},{"issue":"1\u20132","key":"3101_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpharm.2005.05.015","volume":"301","author":"PG Royall","year":"2005","unstructured":"Royall PG, Huang CY, Tang SW, Duncan J, Van-de-Velde G, Brown MB. The development of DMA for the detection of amorphous content in pharmaceutical powdered materials. Int J Pharm. 2005;301(1\u20132):181\u201391. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.05.015.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03101-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:46:01Z","timestamp":1751906761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03101-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03101-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no known competing interests or personal relationships that could have influenced this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"105"}}